Page 11 - American Society For Transplantation News Today : Breaking News, Live Updates & Top Stories | Vimarsana

ADI-001 demonstrated 71% overall response rate (ORR) and 63% complete response (CR) rate across all dose levels in patients with median 4 prior lines of therapy; 50% of patients enrolled had previously progressed on anti-CD19 chimeric antigen receptor T cell (CAR T) therapy 83% ORR and 67% CR rate observed in heavily pre-treated patients who had progressed on prior CAR T Six-month CR rate consistent with autologous CAR T cell therapy Favorable safety with no significant incidence of CRS (cytokine release syndrome) or ICANS (immune effector cell associated neurotoxicity syndrome) Robust pharmacokinetic profile in dose level 4 (DL4) with Cmax and Day 28 persistence exceeding approved CD19 autologous CAR T therapy Plan to transition ADI-001 program into potentially pivotal Phase 2 study in post-CAR T large B-cell lymphoma (LBCL) patients in first half of 2024 Clinical update from additional post-CAR T LBCL patients expected in second half of 2024 Company to host investor web

United statesAdicet bioChen schorFrancesco galimiAmerican society for transplantationCompany twitterAdicet bio incExchange commissionInternational prognostic indexSenior vice presidentChief medical officerChief executive officerEfficacy dataEfficacy evaluable patientsCommon terminology criteriaAdverse events